Madrigal Pharmaceuticals CFO Sells Shares to Cover Tax Obligations

On March 2, 2026, Mardi Dier, Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals (NASDAQ:MDGL), sold 1,183 shares of the company’s common stock for a total of $505,389. The sale was conducted at an average price of $427.21 per share.

Reason for the Sale

The transaction was specifically undertaken to cover tax withholding obligations related to the vesting of previously awarded restricted stock units (RSUs). This is a common practice for executives to meet their tax liabilities when equity awards vest.

Dier’s Remaining Holdings

Following this sale, Mardi Dier continues to hold 9,257 shares of Madrigal Pharmaceuticals stock.

SEC Filing Details

The sale was reported to the Securities and Exchange Commission (SEC) via a Form 4 filing on March 2, 2026. View the SEC Form 4 filing here.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for liver diseases.

Disclaimer: This information is based on publicly available data from SEC filings and news reports as of March 3, 2026.